
Radiation Oncologist at @LevineCancer @AtriumHealth and Southeast #radonc (SERO). #hncsm, #pcsm, #lcsm, #biostats. Tweets=my opinion.
Charlotte, NC
Joined October 2015
- Tweets2.4K
- Following1.2K
- Followers2.3K
- Likes3.1K
Pinned Tweet
Stoked to receive my copy of ECRO, 2nd Edition! Each chapter revised & updated with multiple new chapters. Back in 2015, I wasn't sure we'd see this day! Thanks to all contributors and @SarahSittenfeld @RTendulkarMD @videtig for heading it up! See here: amzn.to/3CjnMOe
Comparative effectiveness research in the presence of known & unmeasurable confounders can do actual harm by making the necessary clinical trials more difficult. @JCO_ASCO
Matthew Ward retweeted
An essay worth reading, for every clinician and patient (with a PrCa paragraph)
The Quiet Half of Good Medicine jamanetwork.com/journals/jam…
Matthew Ward retweeted
"When we tell a patient they have prostate cancer, we mean the pathologist has looked at prostate biopsy cores under a microscope and saw areas without a basal cell layer; what the patient hears, however, is something entirely different" academic.oup.com/jnci/advanc…
Matthew Ward retweeted
Does treatment intensification really put men with prostate cancer at greater fracture risk? 🦴
sciencedirect.com/science/ar…
Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform
A secondary STAMPEDE analysis evaluated fracture-related hospitalisation (FRH) among 3,102 men with #ProstateCancer receiving standard therapy with or without abiraterone💊based intensification.
➡️ In metastatic disease, abiraterone significantly reduced 5-year FRH compared with standard care, both alone and with enzalutamide.
➡️No significant difference emerged in non-metastatic disease.
✅These findings challenge concerns that abiraterone-based intensification increases fracture risk, suggesting improved metastatic bone control may instead reduce clinically significant fractures.
@GrayStruan , @JanetBrown980 , @mccloskey_e , @wmcross , @MaxParmarMRCUCL , @mattsydes , @Prof_Nick_James
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Matthew Ward retweeted
Proton therapy theoretically has better dosimetry than photon therapy for prostate cancer. ☢️
So did it actually lead to better outcomes?
We review the history, physics, and clinical trial outcomes.
youtu.be/gu8Ekd5mTbw
Matthew Ward retweeted
There comes an age where you don't care how you look in photos anymore.
You just want to look good in MRIs, Ultrasounds, and CT Scans.
Matthew Ward retweeted
1/n This is some brilliant investigatory work by @drbeckta. Nothing to add to his substantive critique of the underlying evidence itself or the incorporation of flawed data into guidelines by benefit managers like EviCore. But how best to remedy? Brief 🧵#radonc #medtwitter
Let's keep adding context, but from a different angle:
EviCore was formally created in 2014/2015 through a merger of MedSolutions and CareCore National.
The oldest EviCore radiotherapy guidelines I personally have archived is from 2019. I believe this was close to, if not THE first...but they make this difficult to find (for obvious and shady reasons).
But we can say with certainty that EviCore themselves deemed LDRT for osteoarthritis "medically necessary" at least as far back as 2019.
So what changed?
Well, though LDRT started its journey of rediscovery in America in 2020/2021, it was still relatively unknown to the public and uncommonly performed in American clinics.
Because LDRT, you know, actually works - more and more of us started to offer it, and patients have the ability to like...talk to each other.
In my own practice, for example, I have never once advertised. All of my LDRT patients are word of mouth self-referrals, or referrals from local doctors after they saw me treat their other patients.
Naturally, as this happened across the country, the public took notice.
In 2025, the radiotherapy professional society ASTRO made benign disease/LDRT the theme of their yearly conference.
As you can see from the Google Trends data, Americans searching for "low dose radiation therapy" really took off in early 2025 - and kept going.
Recently, this culminated in an article appearing on NBC's "Today" website, authored by @LaVarsovienne.
It was a classic, feel-good story of LDRT literally making a person, well...feel good.
This article was published on June 16th, 2026, at 1:08PM.
As seen in the Google Trends data, June 2026 is currently the absolute pinnacle of public interest in LDRT.
Which makes sense. "Today" is a massive, international platform. A lot of people saw it.
Almost certainly the people at EviCore saw it.
Which is why the PDF metadata of EviCore's latest guidelines - the one where they abruptly reverse course on LDRT - is extremely interesting.
What are the chances that this PDF was created on June 17th, 2026, at 11:13AM?
As in: 22 hours after one of the biggest platforms in the world runs a story on the benefits of LDRT, the largest benefits manager in the country creates the PDF of their newest guidelines, reversing course on covering this exact treatment, after explicitly covering it for nearly a decade?
Based on a fraudulent AI slop meta-analysis paper?
Really?
I mean sure, it COULD be a coincidence.
Or it could be that EviCore had already drafted most (all?) of this new version, saw this "Today" article drop on a Tuesday, internally said "nope, shut it down", and within 24 hours created this nonsensical non-coverage.
That's quite a coincidence for a company known to utilize their own AI platforms to make immediate, slash-and-burn decisions.
Within that context, it could be considered a consistent pattern of behavior.
Has anyone re-read that @statnews investigation into EviCore lately? The one from last year?
It's certainly compelling!
Matthew Ward retweeted
Honored to be included in this group that has done so much for our patients, the specialty and ASTRO!
@LevineCancer @AtriumHealth @WakeCancer
2026 ASTRO Fellow Spotlight Series:
Congratulations to Stuart Burri, MD, from the Southeast Radiation Oncology Group on being named a 2026 ASTRO Fellow!
We look forward to recognizing you at #ASTRO26.
View the list of 2026 Fellows: ow.ly/MCPw50Zv2gS
@stuxrt
Matthew Ward retweeted
I’m trying to actually start and run companies that cut the cost of healthcare.
CostPlusDrugs.com
Costpluswellness.Com
Business.CostPlusDrugs.com
Manufacturing pediatric cancer and other drugs that are in short supply, in dallas.
Talking to every politician, or group of politicians that wants to discuss HC
Trying to explain to CEOs of self insured companies , that the big conglomerates they work with are not only screwing their company over, their ignorance about HC benefits is why HC is so expensive in this country. If they stopped doing business with the conglomerates, prices would drop for more than the 160m employees they cover. They would drop for everyone
All day. Every. Day.
Matthew Ward retweeted
Excited to share the results of the #ARTO trial. After a median f-up of 53 months, Adding SBRT to abiraterone + ADT significantly improved overall survival (HR 0.55). @dicataldovanes1 @BarbaraJereczek @Ric_Campi @ChadTangMD @TheLancetOncol @ESTRO_RT
authors.elsevier.com/a/1nM82…
Matthew Ward retweeted
Replying to @f2harrell
I have yet to have a single patient ask me: “doctor, if the treatment does nothing to help me (and is ignorable), what is the probability of more extreme data if they ran the trial over and over again”.
Matthew Ward retweeted
❗️ The OLIGOMA trial results just dropped at #ESTRO26 and they are massive. A 15-month improvement in median PFS for OMD breast cancer (HR = 0.48). This adds to the growing mountain of evidence that MDT (Metastasis-Directed Therapy) works. Lets’s go 🧵 1/n
Matthew Ward retweeted
If insurance companies can deny care and call it "medically unnecessary", why aren't they required to have malpractice insurance doe when they get it wrong and someone gets sicker or tragically dies ?
Matthew Ward retweeted
At @JAMA_current today, 2 radiologists publish what should be the consent form for a total body MRI in healthy people
Note: "no major medical society recommends whole-body MRI screening in the general population because it is unproven, and the harms likely outweigh the benefits."
jamanetwork.com/journals/jam…
Matthew Ward retweeted
The big one: confusing association with causation. Your observational cohort study does not show that treatment X *causes* outcome Y. You can adjust for confounders, but you can't adjust your way into a causal claim.
And please stop fitting a 7-variable logistic regression when you have 10 events. Your model didn't converge — it hallucinated.
Matthew Ward retweeted
#ASCOGU26
ARTO trial (Ph2, n=157; f/u: 53 mo): Abiraterone +/- SBRT in 1L oligometastatic CRPC
Benefit with SBRT:
🔷 bPFS: HR 0.49 (p<0.001)
🔷 rPFS: HR 0.48 (p<0.001)
🔷 OS: HR 0.55
🔷 PCSS: HR 0.37 (p=0.006)
📌63% relative reduction in prostate cancer–specific death with metastasis-directed SBRT.
@urotoday
Matthew Ward retweeted
Want to know the craziest part about insurance company Pre Authorization Denials ?
The insurance company defines the network of providers the patient can use
When they deny care, they are effectively saying "we don't trust the judgement of the doctors we require you to use" 🤯🤯🤯
Matthew Ward retweeted
Radiation oncology runs some of the most advanced workflows in medicine, yet its data has remained locked inside specialized systems for decades.
@HeyEpic's new FHIR endpoints, aligned with the CodeX radiotherapy effort, begin turning treatment plans, dose delivery, and therapy progress into interoperable data instead of HL7v2 message archaeology.
Yes, I’m a dork for this stuff, but it’s really quite cool!
Matthew Ward retweeted
Important study shorturl.at/BJKye with super editorial by @NehaVapiwala @ASTRO_org. #prostatecancer patients are often surprised to hear;
1) you have ≤10% risk of prostate only failure and
2) you may not want surgery then anyway!
Great alternatives available #pcsm @gu_onc #radonc
New study in JAMA Oncology: When prostate cancer returns after radiation, focal therapy is as effective as full surgery at 10 years. Surgery had higher risk of complications.
@JAMAOnc @OncoAlert @APCCC_Lugano #ProstateCancer



































